Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®
Abeona Therapeutics announced the activation of Cincinnati Children’s as the seventh Qualified Treatment Center for ZEVASKYN, its gene therapy for RDEB. Cincinnati Children’s is noted as one of the largest Epidermolysis Bullosa centers in the US, a move that significantly broadens patient access to the first and only autologous cell sheet-based gene therapy for this condition.
Key figures
- Qualified treatment center count
- 7
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.